CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast...
Phase 3
Berlin, Germany and 117 other locations
This study will compare DS 8201a to standard treatment.Participants must have HER2 breast cancer that has been treated before.Their ...
Phase 3
Berlin, Germany and 226 other locations
look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast...
Phase 3
Berlin, Germany and 147 other locations
This is a single-arm, open-label phase IV study of patients with advanced HR+/HER2- breast cancer who are treated first line with r...
Phase 4
Berlin, Germany and 51 other locations
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer....
Phase 3
Berlin, Germany and 446 other locations
(BMs), with previously-treated advanced/metastatic HER2-positive breast cancer whose disease has progressed on prior anti-HER2-base...
Phase 3
Berlin, Germany and 80 other locations
PREcoopERA is a randomized (2:2:1), multicenter, open-label, three-arm (A, B, C), Window-of-Opportunity (WOO) trial to evaluate the activity and safe...
Phase 2
Berlin, Germany and 43 other locations
The treatment of patients with HER2 positive early breast cancer has continuously improved over the last decades. Up to now both, t ...
Phase 4
Berlin, Germany and 10 other locations
Phase III, prospective, multi-center, randomized, open label, parallel group, study in patients with HER2-negative breast cancer wi...
Phase 3
Berlin, Germany and 162 other locations
with hormone receptor-positive (HR-positive), HER2-negative advanced breast cancer (aBC) who have not received prior therapy for ad...
Phase 2
Berlin, Germany and 89 other locations
Clinical trials
Research sites
Resources
Legal